GAITHERSBURG, Md., Nov. 13, 2024 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), a global company advancing protein-based vaccines with its Matrix-M™ adjuvant, today announced that it will participate in the Jefferies London Healthcare Conference.
Conference Details: | ||||
Fireside Chat | ||||
Date: | Wednesday, November 20, 2024 | |||
Time: | 11:00 – 11:25 a.m. Greenwich Mean Time | |||
Location: | London, United Kingdom | |||
Moderator: | Roger Song, MD, CFA, Equity Analyst | |||
Novavax participants: | John C. Jacobs, President and Chief Executive Officer and Additional Management Team Members | |||
Investor Meetings | ||||
Date: | Wednesday, November 20, 2024 | |||
Recordings
A replay of the fireside chat will be available on the Events & presentations page of the Company's website at ir.novavax.com for 30 days from the date of the conference.
About Novavax
Novavax, Inc. (Nasdaq: NVAX) promotes improved health by discovering, developing and commercializing innovative vaccines to help protect against serious infectious diseases. Novavax, a global company based in Gaithersburg, Md., U.S., offers a differentiated vaccine platform that combines a recombinant protein approach, innovative nanoparticle technology and Novavax's patented Matrix-M adjuvant to enhance the immune response. The Company's portfolio includes its COVID-19 vaccine and its pipeline includes COVID-19-Influenza Combination and stand-alone influenza vaccine candidates. In addition, Novavax's adjuvant is included in the University of Oxford and Serum Institute of India's R21/Matrix-M malaria vaccine. Please visit novavax.com and LinkedIn for more information.
Contacts:
Investors
Luis Sanay, CFA
240-268-2022
This email address is being protected from spambots. You need JavaScript enabled to view it.
Media
Giovanna Chandler
202-709-5563
This email address is being protected from spambots. You need JavaScript enabled to view it.
| Last Trade: | US$7.40 |
| Daily Change: | -0.15 -1.99 |
| Daily Volume: | 3,814,881 |
| Market Cap: | US$1.200B |
May 19, 2025 | |
Recursion Pharmaceuticals is a clinical stage TechBio company leading the space by decoding biology to industrialize drug discovery. Enabling its mission is the Recursion OS, a platform built across diverse technologies that continuously expands one of the world’s largest....
CLICK TO LEARN MORE
Astria Therapeutics is a biopharmaceutical company, and our mission is to bring life-changing therapies to patients and families affected by rare and niche allergic and immunological diseases. Our lead program, STAR-0215, is a monoclonal antibody inhibitor of plasma kallikrein in clinical development...
CLICK TO LEARN MORE
